Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by JPPOUGET
Group name EquipeJPP
Item Type Journal Article
Title Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities
Creator Lapierre et al.
Author Ariane Lapierre
Author Laura Bourillon
Author Marion Larroque
Author Tiphany Gouveia
Author Céline Bourgier
Author Mahmut Ozsahin
Author André Pèlegrin
Author David Azria
Author Muriel Brengues
Abstract Personalized treatment and precision medicine have become the new standard of care in oncology and radiotherapy. Because treatment outcomes have considerably improved over the last few years, permanent side-effects are becoming an increasingly significant issue for cancer survivors. Five to ten percent of patients will develop severe late toxicity after radiotherapy. Identifying these patients before treatment start would allow for treatment adaptation to minimize definitive side effects that could impair their long-term quality of life. Over the last decades, several tests and biomarkers have been developed to identify these patients. However, out of these, only the Radiation-Induced Lymphocyte Apoptosis (RILA) assay has been prospectively validated in multi-center cohorts. This test, based on a simple blood draught, has been shown to be correlated with late radiation-induced toxicity in breast, prostate, cervical and head and neck cancer. It could therefore greatly improve decision making in precision radiation oncology. This literature review summarizes the development and bases of this assay, as well as its clinical results and compares its results to the other available assays.
Publication Cancers
Volume 14
Issue 9
Pages 2097
Date 2022-04-22
Journal Abbr Cancers (Basel)
Language eng
DOI 10.3390/cancers14092097
ISSN 2072-6694
Library Catalog PubMed
Extra Number: 9 PMID: 35565227 PMCID: PMC9099838
Tags first-last-coresponding, last, late toxicities prediction, personalized treatment, review
Date Added 2023/11/23 - 12:48:16
Date Modified 2024/12/15 - 03:59:51
Notes and Attachments PubMed entry (Attachment)
Texte intégral (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés